Global study finds people with haemophilia fight challenges in their professional career but succeed in completing education and getting a job

 

Paris, France (July 9, 2012) – The first results from a new global study mapping the psychosocial aspects of living with haemophilia show eight out of 10 people with haemophilia have experienced a negative impact of haemophilia on their professional career, with one in five believing they have lost a job because of haemophilia.i However, the findings from the study also show that 85% of people with haemophilia describe themselves as educated and only 8% are not able to find employment.(1)

 

The results are the first findings from the HERO (Haemophilia Experiences, Results and Opportunities) study and will be presented at the World Federation of Hemophilia 2012 World Congress in Paris 9–11 July 2012.(2) Besides employment, the HERO study has also examined relationships, sexual health, treatment and management of haemophilia, information and knowledge and quality of life. Findings from these areas will also be presented throughout the congress.

 

“Treatment of haemophilia has advanced greatly over the past decades, but psychosocial issues can still be a challenge for people with haemophilia, for example societal stigma,” Professor at Department of Clinical Epidemiology and Biostatics, McMaster University, Canada, and member of the HERO International Advisory Board, Alfonso Iorio said. “The insights from the HERO study will provide much needed evidence to support advocating for better comprehensive haemophilia care.”

 

Further data and background info on the HERO study will be available via the following link:

 

http://www.novonordisk.com/about_us/improving_haemophilia/researchoutline-and-results.asp

 

 

About the HERO study

 

HERO (Haemophilia Experiences, Results and Opportunities) is an international, multidisciplinary initiative led by the HERO International Advisory Board and is supported by Novo Nordisk. At the heart of the HERO initiative is the HERO study, the largest ever multinational multi-method study of the psychosocial experience of people with haemophilia, parents and healthcare professionals. The survey covers themes around employment, relationships, sexual health, treatment and management of haemophilia, information and knowledge and quality of life and consists of:

 

  • An extensive literature review to assess the existing literature and establish gaps in knowledge – published in Haemophilia (Cassis et al. 2011).(3)
  • Qualitative research among 150 people with haemophilia, parents and healthcare professionals from seven countries.
  • Quantitative research among 1,236 people (≥18 years of age) with haemophilia and parents of children with haemophilia (< 18) across 10 countries.

 

HERO aims to improve outcomes in haemophilia by calling for and enabling enhanced psychosocial support based on increased understanding and awareness of the issues.

 

 

About haemophilia

 

Haemophilia is a rare blood clotting disorder. Internal bleeding into the joints, muscles and other tissues can cause severe pain, joint damage and disability. The worldwide incidence of haemophilia A is approximately one case per 5,000 males, approximately 30% of whom have no family history. Haemophilia B occurs in one case per 25,000 males. It is estimated that around 400,000 males have haemophilia A or B.

 

 

Novo Nordisk

 

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com

 

 

References 

  1. Forsyth A, Gregory M and Iorio A on behalf of the HERO International Advisory Board. Demographic Characteristics of People with Haemophilia in the Haemophilia Experiences Results Opportunities (HERO) study. Presented at World Federation of Hemophilia 2012 World Congress, Paris, France. Session: POMO-Poster I Monday, Poster Board Number: 199.
  2. Posters 22, 86, 87, 88, 148, 199, 200, 218 and oral presentation FP-MO-04.4 – MEDICAL at World
  3. Federation of Hemophilia 2012 World Congress, Paris, France.
  4. Cassis FRMY, Querol F, Forsyth A, Iorio A on behalf of the HERO International Advisory Board. Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. Haemophilia 2011, 101-114.

 


 

Novo Nordisk A/S, 09.07.2012 (tB).

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…
Minimalinvasive Geräte warnen ungenügend vor Unterzuckerung
Typ-1-Diabetes und Hashimoto-Thyreoiditis treten häufig gemeinsam auf

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung